Prompts Gain of function. Oncogenes Mutated forms of proto-oncogenes Examples of oncogenes Loss of function. Examples of tumor suppressor genes Tumor suppressor genes Inherited cancer The Knudson's 2-hit hypothesis Both inherited and sporadic cancers. Submitted Answers Choose a match Choose a match Choose a match. Choose a match Choose a match. Choose a match Choose a match Choose a match. Choose a match Choose a match ▼ ▼ ▼ ▼ ▼ ▼ O O is seen in oncogenes, leading to cancer. protect cells from uncontrolled proliferation. O are; CMYC, KRAS & ErBb2 O involve Tumor suppressor genes O requires loss of function in both alleles. are not involved in inherited forms of cancer are oncogenes. is of relevance to inherited cancers. is seen in tumor suppressor genes, leading to cancer. O are; BRCA1, BRCA2 & TP53

Prompts Gain of function. Oncogenes Mutated forms of proto-oncogenes Examples of oncogenes Loss of function. Examples of tumor suppressor genes Tumor suppressor genes Inherited cancer The Knudson's 2-hit hypothesis Both inherited and sporadic cancers. Submitted Answers Choose a match Choose a match Choose a match. Choose a match Choose a match. Choose a match Choose a match Choose a match. Choose a match Choose a match ▼ ▼ ▼ ▼ ▼ ▼ O O is seen in oncogenes, leading to cancer. protect cells from uncontrolled proliferation. O are; CMYC, KRAS & ErBb2 O involve Tumor suppressor genes O requires loss of function in both alleles. are not involved in inherited forms of cancer are oncogenes. is of relevance to inherited cancers. is seen in tumor suppressor genes, leading to cancer. O are; BRCA1, BRCA2 & TP53

Human Heredity: Principles and Issues (MindTap Course List)

11th Edition

ISBN:9781305251052

Author:Michael Cummings

Publisher:Michael Cummings

Chapter8: The Structure, Replication, And Chromosomal Organization Of Dna

Section8.4: The Watson-crick Model Of Dna Structure

Problem 1GR: Two genes associated with breast cancer, BRCA1 and BRCA2, were discovered in 1994 and 1995,...

See similar textbooks

Similar questions

There are three broad categories of cancer-related genes: proto-oncogenes, tumor suppressor genes, and DNA stability/repair genes. Define each of these categories and indicate which one you think the RB1 gene belongs to and why.
There are three broad categories of cancer-related genes: proto-oncogenes, tumor suppressor genes, and DNA repair/stability genes. Distinguish between these three groups, then indicate which you think RB1 belongs to.
Some cancers are consistently associated with the deletion of a particularpart of a chromosome. Does the deleted region contain an oncogene or atumor-suppressor gene? Explain.
In the treatment of cancer, the basis for many types of chemotherapyand radiation therapy is that mutagens are more effective at killingdividing cells than nondividing cells. Explain why. What are possibleharmful side effects of chemotherapy and radiation therapy?
Define about this- Cancer Cells Contain GeneticDefects Affecting Genomic Stability ?
Why is it important to model cancer through the generation of induced pluripotent stem cells ? Explain in detail the main findings.
Why is it important to model cancer through the generation of induced pluripotent stem cells ? Explain in detail the main findings. Please sort as a list.
Why is it important to model cancer through the generation of induced pluripotent stem cells ? Please list item by item. Explain in detail the main findings.
Research cancer mutation. Provide the link to the research article that gives you your information. One good resource to use is PubMed. Then answer the following questions, in 3 paragraphs, 3-5 sentences each. 1. What kind of disease/cancer does this mutation cause? 2.What happens during transcription to cause this mutation? 3. Is this trait passed on to progeny? Can the progeny be a carrier or simply affected?
Many of the mutations in cancer samples are not necessarily driver mutations, but rather passenger mutations that are along for the ride. Just because the tumors with a strong environmental component possess a higher frequency of mutations does not mean more oncogenes or more failure of tumor suppressors is occurring. Hematologic childhood cancers have a lower frequency of mutations than tumors with a strong environmental component such as lung cancers and melanoma; WHY?
Two genes associated with breast cancer, BRCA1 and BRCA2, were discovered in 1994 and 1995, respectively, and shortly thereafter, were patented by Myriad Genetics, a company based in Utah. Under the patents, testing for mutations in these genes could only be performed by Myriad, at costs from 300 to 3,000. Myriad also patented the process of analyzing the results of such tests, preventing anyone who obtains the sequence of their BRCA genes by other means (which itself would probably be patent infringement) from interpreting the information. The idea that genes can be patented has been a contentious issue from the beginning. Patents are not granted for products of nature, meaning that genes inside the body are not patentable, but biotech companies successfully argued that by removing a gene from the human body, purifying it, and then obtaining its DNA sequence, they created something not found in nature, and which is therefore a patentable invention. The U.S. Patent Office found the argument persuasive, but opponents argue that genes are parts of our bodies and can be identified but not invented. Biotech companies argue that without the protection offered by patents, they would have no incentive for research and development of diagnostic tests. In Europe, patents for BRCA1 and BRCA2 were revoked in 2004 because they did not meet the standards for a patent. After more than a decade of legal disputes, the patents were partially restored in 2008 on a very restricted basis. In the United States, a lawsuit, focused on the patents for the BRCA genes, was filed in May 2009. The suit challenges the basic idea that genes are patentable. In November 2009, the judge ruled that the lawsuit can proceed, and the case is moving forward. In March 2010, a federal court invalidated Myriad Genetics patent on these genes. In August 2011, the U.S. Court of Appeals reversed the lower courts decision and ruled that gene sequences isolated from cells are not a product of nature and are therefore patentable. The case went to the U.S. Supreme Court, which ordered the appeals court to reconsider the case. The Federal Appeals Court did not change its decision, and the case once again, went to the U.S. Supreme Court. A unanimous decision in June 2013 invalidated Myriads patents on the basis that isolating a gene from nature does not make it patentable. This is a landmark decision on gene patenting with widespread ramifications for the biotechnoloogy industry. Will this decision reduce the incentives for companies to invest in new diagnostic tests that would be used by cancer victims or those with serious genetic disorders?
What is the difference between a proto-oncogene and a tumor-suppressor gene?